Medical Cannabis Research Australia
FINDINGS:
Our meta-analysis outcomes show that cannabinoid administration was associated with reductions in subjective pain across included studies, making them viable candidates for pain management and treatment. Moreover, meta-regression results suggested that drug administration condition and sample size predicted pain reduction effects. Finally, we observed that sample sex composition was associated (although, not statistically significant) with observed pain reduction, suggesting that this may be an important biological variable when considering cannabis-induced pain reduction. As social, societal, and political attitudes towards cannabis evolve, it is becoming increasingly important to provide enhanced scientific understanding regarding risks and potential therapeutic applications. Such understanding should lead to more informed decision-making regarding cannabis among patients, care providers, and law makers.
Exp Clin Psychopharmacol. 2019 Aug; 27(4): 370–382.
FINDINGS:
In this survey, pain clinicians experienced in prescribing cannabis over prolonged periods view it as an effective and relatively safe treatment for chronic pain, based on their own experience. Their responses suggest a possible change of paradigm from using cannabis as the last resort.
PubMed.gov – J Am Pharm Assoc (2003). 2019 Sep 5. pii: S1544-3191(19)30353-X. doi: 10.1016/j.japh.2019.07.015.
FINDINGS:
The use of cannabis and cannabinoids via certain administration routes could reduce different types of pain. Product developers could consider our findings as part of their product design so that the effective route of cannabis and cannabinoids for pain control can be achieved.
PubMed.gov – J Am Pharm Assoc (2003). 2019 Sep 5. pii: S1544-3191(19)30353-X. doi: 10.1016/j.japh.2019.07.015.
April 2018 Current Opinion in Pharmacology 40:104-109
Front. Pharmacol., 13 November 2018
INTRODUCTION:
A set of guidance documents has been made available to assist doctors and their patients who choose to prescribe medicinal cannabis in Australia under current access schemes. These have been developed based on reviews of available evidence for the use of medicinal cannabis in five different settings. Included is an overview addressing the evidence base for medicinal cannabis therapy generally as well as specific documents relating to medicinal cannabis in the treatment of palliative care, epilepsy, chemotherapy-induced nausea and vomiting (CINV), multiple sclerosis (MS) and chronic pain.
This document reflects the evidence supporting the use of medicinal cannabis in treating chronic pain and the recommendations of the Chronic Pain Working Group.
Note: These guidance documents are based on evidence available at the time of publication and will be updated as new evidence emerges. Each document should be read in conjunction with the ‘Guidance to the use of medicinal cannabis in Australia – Overview‘.
In September 2017 a workshop was held in Sydney to discuss the review of the available evidence for the use of medicinal cannabis (medicinal cannabis) in patients with chronic non-cancer pain (CNCP). Workshop participants included representatives from consumer groups, medical colleges, special societies and states and territories.
For more information, please follow the link for TGA Guidance.
J Pain Res. 2019 May 20;12:1577-1604. doi: 10.2147/JPR.S192174. eCollection 2019.